Despite being off-patent for many years, Humalog and other insulin brands continue to make high sales, with Lilly booking around $3 billion from its product last year, $1.8 billion of which was ...

Advocates for diabetes patients who need insulin to survive worry the nation's supply is unreliable. Meanwhile, use of ...

Three drug companies dominate the U.S. insulin market: Novo Nordisk, Eli Lilly and Sanofi. Last spring, Eli Lilly reported its drugs Humalog and insulin lispro were in short supply. Novo Nordisk ...

(KKTV) - A shortage of Eli Lilly insulin products continues to put Southern Colorado residents in a bind. The company announced last month that their 10-milliliter vials of Humalog and Insulin ...

Insulin prices have skyrocketed in recent years, working a hardship on the growing number of diabetics in the US. Progressive ...

Insulin lispro, the rapid-acting component of Humalog Mix75/25, has been shown to be equipotent to Regular human insulin on a molar basis. Instruct patients on diet, exercise, blood or urine ...

The primary activity of insulin including Humalog Mix50/50 is the regulation of glucose metabolism. Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat ...

The reason a price cap is being targeted is due to the rapid increase in the cost of insulin products over the last few decades. According to research, one vial of Humalog (insulin lispro ...

Which insulin brands are in shortage and why? Earlier this year, Eli Lilly reported temporary shortages of Humalog and insulin lispro in 10-milliliter vials. The company said new regulations had ...

Death is imminent," Wright said. Three drug companies dominate the U.S. insulin market: Novo Nordisk, Eli Lilly and Sanofi.